Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Additionally we are shipping Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) Antibodies (49) and Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) Proteins (13) and many more products for this protein.
Showing 5 out of 8 products:
Mouse (Murine) TNFRSF11B ELISA Kit for Sandwich ELISA - ABIN2685709
Ohmori, Makita, Funamizu, Hirooka, Hosoi, Orimo, Suzuki, Ikari, Nakajima, Inoue, Hata: Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. in Journal of human genetics 2002
Show all 4 references for ABIN2685709
Rat (Rattus) TNFRSF11B ELISA Kit for Sandwich ELISA - ABIN456064
Che, Bing, Akhtar, Tingting, Kezhou, Rong: Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity. in Journal of translational medicine 2013
Regional variation of periosteal activity at the mandibular ramus is regulated by differential expression of osteoprotegerin.
Low-frequency vibration may promote the osteogenic differentiation capability of BMSC probably through regulating the OPG/RANKL (show TNFSF11 ELISA Kits) mRNA expression.
OPG (show TNFSF11 ELISA Kits) expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation.
the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice
identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis
Osteoprotegerin is increased in metabolic syndrome and promotes adipose tissue proinflammatory changes.
Osteoprotegerin inhibits vascular calcification by regulating the procalcific effects of RANKL (show TNFSF11 ELISA Kits) and Il6 (show IL6 ELISA Kits) on vascular smooth muscle cells.
These results indicate that OPG (show TNFSF11 ELISA Kits) derived either from the bone marrow or from the vessel wall is sufficient to slow down lesion progression and vascular calcification independent of bone turnover.
High concentrations of alendronate decrease the expressions of OPG (show TNFSF11 ELISA Kits) and RANKL (show TNFSF11 ELISA Kits) in cultured osteoblasts.
In a xenograft model, increased osteoprotegerin expression correlated with a delay to pathologic fracture suggesting a potential role for mTOR (show FRAP1 ELISA Kits) inhibitors in the treatment of neuroblastoma (show ARHGEF16 ELISA Kits) bone metastases.
Data indicate in TLR4 (show TLR4 ELISA Kits)(-/-) mice, higher expression levels of IL-1beta (show IL1B ELISA Kits) and lower expression levels of VEGF (show VEGFA ELISA Kits), RANK, RANKL (show TNFSF11 ELISA Kits) and OPG (show TNFSF11 ELISA Kits) were detected at late time points (> postoperative 4 days).
Coptisine inhibits RANKL (show TNFSF11 ELISA Kits)-induced NF-kappaB (show NFKB1 ELISA Kits) phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL (show TNFSF11 ELISA Kits) and OPG (show TNFSF11 ELISA Kits) gene expression in osteoblastic cells.
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis (By similarity).
tumor necrosis factor receptor superfamily, member 11b
, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
, tumor necrosis factor receptor superfamily member 11B
, osteoclastogenesis inhibitory factor